Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Secretory component

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Secretory component. Displaying page 1 of 1.
    EudraCT Number: 2022-002891-35 Sponsor Protocol Number: RECHMPL22_0123 Start Date*: 2023-01-04
    Sponsor Name:University Hospital of Montpellier
    Full Title: REVErsing airway Remodelling with Tezepelumab (REVERT): a protocol for a double-blind randomized controlled trial for patients with asthma
    Medical condition: exacerbating asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001462-33 Sponsor Protocol Number: 26866138-MMY-2045 Start Date*: 2008-01-03
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of VELCADE® in combination with Dexamethasone or VELCADE® in combination with Dexamethasone ...
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) LT (Completed) HU (Completed) ES (Completed) GR (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001330-29 Sponsor Protocol Number: LENALID01 Start Date*: 2015-01-30
    Sponsor Name:Ernesto Pérez Persona
    Full Title: No
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002157-29 Sponsor Protocol Number: 3 Start Date*: 2015-01-20
    Sponsor Name:Ernesto Pérez Persona
    Full Title: Clinical, multicenter, single-arm, with a scheme of treatment with low doses of Bortezomib / Melphalan / Prednisone (Velcade) (MPV) in patients with multiple myeloma (MM) newly diagnosed symptomati...
    Medical condition: multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10028566 Myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000712-29 Sponsor Protocol Number: BV2012/05 Start Date*: 2012-09-03
    Sponsor Name:OM Pharma SA
    Full Title: Clinical and immune modifying capacity of Broncho-Vaxom® tested by LPS challenge in healthy volunteers A randomized double-blind placebo-controlled trial
    Medical condition: healthy volunteers intended indication : Experimental induced bronchitis in healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021832 Infection induced LLT
    14.1 10021881 - Infections and infestations 10006451 Bronchitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002675-41 Sponsor Protocol Number: CRAD001C2455 Start Date*: 2007-05-22
    Sponsor Name:Universitaetsklinikum Schleswig-Holstein
    Full Title: A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma
    Medical condition: Multiple Myeloma (Salmon-Durie stage II or III, Relapsed or refractory disease after failure of two or more treatment regimens)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001842-34 Sponsor Protocol Number: DOXIL-MMY-3001 Start Date*: 2004-11-29
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development
    Full Title: A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
    Medical condition: Recurred or relapsed multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000044-18 Sponsor Protocol Number: GEM2017FIT Start Date*: 2018-07-04
    Sponsor Name:Fundación PETHEMA
    Full Title: Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 ...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001897-26 Sponsor Protocol Number: C0328T05 Start Date*: 2006-09-07
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2 Multicenter Study of CNTO 328 (Anti Interleukin 6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma
    Medical condition: relapsed or refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001142-28 Sponsor Protocol Number: PO-3887 Start Date*: 2015-12-30
    Sponsor Name:Fondazione EMN Italy Onlus
    Full Title: A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE III STUDY OF POMALIDOMIDE-DEXAMETHASONE (Pom-dex) versus POMALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE (Pom-cyclo-dex) IN MULTIPLE MYELOMA (MM) PATIENTS WH...
    Medical condition: MULTIPLE MYELOMA (MM) PATIENTS WHO EXPERIENCE BIOCHEMICAL (EARLY TREATMENT) OR CLINICAL RELAPSE (LATE TREATMENT) DURING LENALIDOMIDE MAINTENANCE TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002326-21 Sponsor Protocol Number: GEM-SELIBORDARA Start Date*: 2018-05-11
    Sponsor Name:Fundación PETHEMA
    Full Title: An Open-label, Multicenter, Phase 2 trial of selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and ...
    Medical condition: Patients with refractory or relapsed and refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004203-41 Sponsor Protocol Number: 54767414MMY2040 Start Date*: 2018-04-26
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-016871-32 Sponsor Protocol Number: 0911001 Start Date*: 2010-06-28
    Sponsor Name:CHU de TOULOUSE
    Full Title: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplan...
    Medical condition: Myeloma, Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028228 Multiple myeloma LLT
    12.0 10028566 Myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 12:38:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA